- Home
- TCBI vs BHVN Comparison
TCBI vs BHVN Comparison
Compare TCBI & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBI
- BHVN
- Stock Information
- Founded
- TCBI 1996
- BHVN 2013
- Country
- TCBI United States
- BHVN United States
- Employees
- TCBI N/A
- BHVN N/A
- Industry
- TCBI Major Banks
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- TCBI Finance
- BHVN Health Care
- Exchange
- TCBI Nasdaq
- BHVN Nasdaq
- Market Cap
- TCBI 3.7B
- BHVN 4.2B
- IPO Year
- TCBI N/A
- BHVN 2017
- Fundamental
- Price
- TCBI $79.58
- BHVN $36.85
- Analyst Decision
- TCBI Hold
- BHVN Strong Buy
- Analyst Count
- TCBI 14
- BHVN 14
- Target Price
- TCBI $79.36
- BHVN $63.15
- AVG Volume (30 Days)
- TCBI 440.5K
- BHVN 752.7K
- Earning Date
- TCBI 04-17-2025
- BHVN 03-03-2025
- Dividend Yield
- TCBI N/A
- BHVN N/A
- EPS Growth
- TCBI N/A
- BHVN N/A
- EPS
- TCBI 1.28
- BHVN N/A
- Revenue
- TCBI $865,346,000.00
- BHVN N/A
- Revenue This Year
- TCBI N/A
- BHVN N/A
- Revenue Next Year
- TCBI $9.16
- BHVN $154.39
- P/E Ratio
- TCBI $62.17
- BHVN N/A
- Revenue Growth
- TCBI N/A
- BHVN N/A
- 52 Week Low
- TCBI $54.68
- BHVN $26.80
- 52 Week High
- TCBI $91.80
- BHVN $62.21
- Technical
- Relative Strength Index (RSI)
- TCBI 46.42
- BHVN 40.96
- Support Level
- TCBI $80.79
- BHVN $38.40
- Resistance Level
- TCBI $82.72
- BHVN $42.82
- Average True Range (ATR)
- TCBI 2.39
- BHVN 2.14
- MACD
- TCBI -0.12
- BHVN -0.16
- Stochastic Oscillator
- TCBI 42.53
- BHVN 0.34
About TCBI Texas Capital Bancshares Inc.
Texas Capital Bancshares Inc is a secured lender, with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. The company's national lines of business provide specialized lending products to businesses throughout the United States. The bank operates in Texas' main metropolitan areas, like Austin, Dallas, Fort Worth, Houston, and San Antonio.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.